Histone deacetylase inhibitors in the treatment of lymphoid malignancies
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023736%3A_____%2F15%3A00011427" target="_blank" >RIV/00023736:_____/15:00011427 - isvavai.cz</a>
Result on the web
<a href="https://www.novapublishers.com/catalog/product_info.php?products_id=54027&osCsid=" target="_blank" >https://www.novapublishers.com/catalog/product_info.php?products_id=54027&osCsid=</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Histone deacetylase inhibitors in the treatment of lymphoid malignancies
Original language description
Vorinostat (Zolinza) and romidepsin (Istodax) have been approved by the US Foodand Drug Administration for the treatment of relapsed and refractory cutaneous and peripheral T-cell lymphomas who have received one or more prior therapies. HDACIs were also successfully used in non-Hodgkin lymphomas. Combinations of HDACIs with hypomethylating agents were effective inHodgkin lymphoma and combinations of HDACIs and proteasome inhibitors have synergistic anti-cancer effect in multiple myeloma cells.
Czech name
—
Czech description
—
Classification
Type
C - Chapter in a specialist book
CEP classification
FD - Oncology and haematology
OECD FORD branch
—
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Book/collection name
Histone deacetylase inhibitors (HDIs): pharmacology, uses and health effects
ISBN
978-1-63482-379-1
Number of pages of the result
32
Pages from-to
31-62
Number of pages of the book
120
Publisher name
Nova Science
Place of publication
New York
UT code for WoS chapter
—